Technology
Health
Biotechnology

Ligand Pharmaceuticals

$113.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (0.12%) As of 11:34 AM EDT today
+$0.14 (0.12%) Today

Why Robinhood?

You can buy or sell LGND and other stocks, options, ETFs, and crypto commission-free!

About LGND

Ligand Pharmaceuticals Incorporated Common Stock, also called Ligand Pharmaceuticals, is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Read More The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Employees
116
Headquarters
San Diego, California
Founded
1987
Market Cap
2.23B
Price-Earnings Ratio
3.24
Dividend Yield
0.00
Average Volume
284.61K
High Today
$115.48
Low Today
$113.50
Open Price
$114.23
Volume
122.65K
52 Week High
$278.62
52 Week Low
$98.56

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

LGND News

BenzingaJul 16

Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP

39

LGND Earnings

$1.02
$1.54
$2.07
$2.59
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Jul 30, Pre-Market

More LGND News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.